TARA Protara Therapeutics, Inc. - Common Stock
关于 Protara Therapeutics, Inc. - Common Stock 公司概况(来自维基百科)
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
阅读更多
Proteon Therapeutics, Inc. is a developer of pharmaceuticals with offices in Waltham, Massachusetts and Kansas City, Missouri.
Company History
Proteon was founded by Dr. F. Nicholas Franano based on technology created at Johns Hopkins University. Major investors in the company include MPM Capital, Rockhill Partners, TVM Capital, Skyline Ventures, Prism VentureWorks, Vectis Life Sciences and Intersouth Partners. They have invested over $72 million in the company.
The company is led by Timothy Noyes, CEO; Steven Burke, CMO; George Eldridge, CFO; and Scott Toner, director of marketing.
On March 5, 2009, the company announced that it had raised $32 million from its existing investors plus MPM Capital and Vectis Life Sciences. Proteon also announced that it had entered into an option agreement to be acquired by Novartis for up to $550 million. The company went public in 2014.
In September 2019, Proteon Therapeutics merged with ArTara Therapeutics.
PRT-201
Proteon is developing PRT-201 (vonapanitase), a drug to improve blood flow following vascular surgery procedures, and, more broadly, is interested in vascular access for hemodialysis and peripheral arterial disease (PAD). PRT-201 is a recombinant human elastase manufactured for Proteon by Lonza.
In September 2008, the company announced that the Food and Drug Administration had granted fast track status to PRT-201.
In December 2016, they announced that the phase III trial of PRT-201 hadn't reached its primary endpoint, causing Proteon's stock price to drop more than 75%.
来源:维基百科 (英语), CC BY-SA 4.0 · 在维基百科上查看 ↗
TARA 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
TARA 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
TARA 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 3 21.4%
- 买入 10 71.4%
- 持有 1 7.1%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
7 位分析师 · 2026-08-13收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-0.31 | $-0.38 | 0.07% |
| 2025年12月31日 | $-0.37 | $-0.33 | -0.04% |
| 2025年9月30日 | $-0.31 | $-0.39 | 0.08% |
| 2025年6月30日 | $-0.35 | $-0.41 | 0.06% |
| 2025年3月31日 | $-0.29 | $-0.46 | 0.17% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| TARA | $286M | -4.0 | — | — | -33.7% | — |
| CNXU | — | — | — | — | — | — |
| GLSI | $300M | -14.7 | — | — | -2159.7% | — |
| PYXS | $72M | -0.9 | -14.2% | -574.5% | -112.9% | — |
| RCEL | $105M | -2.0 | 11.5% | -67.8% | 328.9% | 82.1% |
| AKBA | $427M | -80.5 | 47.5% | -2.3% | -17.3% | — |
| ALEC | $172M | -1.1 | -79.1% | -679.2% | -280.7% | — |
| EBS | $644M | 13.3 | -28.8% | 7.1% | 9.9% | — |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | — |
| NBP | — | — | — | — | — | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 16
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| R&D Expense | $43M | $32M | $25M | $17M | $21M | $12M | $4M | $12M | $22M | $19M | $12M | $6M | |
| SG&A Expense | $22M | $17M | $19M | $21M | $26M | $22M | $4M | $10M | $9M | $10M | $8M | $4M | |
| Operating Expenses | $65M | $49M | $44M | $67M | $47M | $34M | $8M | $21M | $30M | $29M | $21M | $11M | |
| Operating Income | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-8M | |
| Interest Expense | · | · | · | · | $0 | $34.0K | · | · | · | · | · | $857.0K | |
| Interest Income | $6M | $4M | $3M | $1M | $237.0K | $500.0K | · | · | · | · | · | · | |
| Other Non-op | $7M | $5M | $3M | $1M | $237.0K | $466.0K | · | $207.0K | $139.0K | $-14.0K | $-651.0K | $5M | |
| Pretax Income | $57M | $45M | · | · | · | · | $-15M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Income Tax | · | · | · | · | · | · | · | · | · | · | · | $-110.0K | |
| Net Income | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| EPS (Basic) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| EPS (Diluted) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 | · | · | · | · | · | · | · | |
| Shares (Basic) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | · | · | · | · | · | · | · | · | |
| Shares (Diluted) | 42,836,129 | 20,592,847 | 11,331,338 | 11,259,615 | 11,232,576 | · | · | · | · | · | · | · | |
| EBITDA | $-65M | $-49M | $-44M | $-67M | $-47M | $-34M | $-15M | · | · | $-29M | $-21M | $-8M |
资产负债表 23
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50M | $163M | $40M | $24M | $36M | $169M | $564.0K | $19M | $21M | $36M | $40M | $69M | |
| Short-term Investments | $106M | $7M | $26M | $60M | $56M | · | · | $2M | $21M | $5M | $25M | $15M | |
| Prepaid Expense | $4M | $2M | $3M | $2M | $2M | $787.0K | $78.0K | $1M | $1M | $1M | $1M | $1M | |
| Other Current Assets | $65.0K | $2.0K | $37.0K | $127.0K | $34.0K | $52.0K | · | · | · | · | · | · | |
| Current Assets | $160M | $172M | $69M | $86M | $93M | $169M | $764.0K | $23M | $43M | $43M | $67M | $85M | |
| PP&E (Net) | $759.0K | $1M | $1M | $2M | $2M | $1M | $459.0K | $263.0K | $259.0K | $372.0K | $224.0K | $83.0K | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $1M | $475.0K | $1M | $971.0K | $937.0K | $665.0K | $467.0K | |
| Accum. Depreciation | $1M | $1M | $824.0K | $483.0K | $236.0K | $119.0K | $16.0K | $827.0K | $712.0K | $565.0K | $441.0K | $384.0K | |
| Goodwill | · | · | · | · | $30M | $30M | · | · | · | · | · | · | |
| Other Non-current Assets | $20.0K | $27.0K | $11.0K | $16.0K | $865.0K | $1M | · | · | $218.0K | $393.0K | $706.0K | $114.0K | |
| Total Assets | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Accounts Payable | $3M | $4M | $2M | $2M | $954.0K | $914.0K | $716.0K | $441.0K | $291.0K | $556.0K | $1M | $917.0K | |
| Accrued Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $3M | $3M | $9M | $5M | $3M | $1M | |
| Current Liabilities | $11M | $11M | $6M | $6M | $4M | $3M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Capital Leases | $2M | $3M | $4M | $5M | $6M | $999.0K | · | · | · | · | · | · | |
| Total Liabilities | $13M | $14M | $11M | $11M | $11M | $4M | $3M | $3M | $9M | $5M | $4M | $2M | |
| Common Stock | $54.0K | $35.0K | $11.0K | $11.0K | $11.0K | $11.0K | $3.0K | · | $18.0K | $17.0K | $16.0K | $16.0K | |
| Paid-in Capital | $499M | $412M | $269M | $263M | $256M | $246M | $11M | $209M | $203M | $198M | $195M | $192M | |
| Retained Earnings | $-302M | $-245M | $-200M | $-160M | $-94M | $-47M | $-13M | $-210M | $-190M | $-160M | $-131M | $-110M | |
| AOCI | $90.0K | $2.0K | $-31.0K | $-688.0K | $-211.0K | · | $3.0K | $5.0K | $-14.0K | · | $-11.0K | $-6.0K | |
| Stockholders' Equity | $196M | $167M | $68M | $102M | $162M | $199M | $-2M | $5M | $35M | $38M | $63M | $82M | |
| Liabilities + Equity | $209M | $181M | $79M | $113M | $173M | $203M | $1M | $24M | $44M | $44M | $68M | $85M | |
| Shares Outstanding | 53,587,260 | 35,044,772 | 11,364,903 | 11,267,389 | 11,235,731 | 11,211,840 | 2,627,533 | 481,091 | 17,674,729 | 16,603,559 | 16,501,500 | 16,448,455 |
现金流 14
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | $123.0K | $57.0K | $30.0K | |
| Stock-based Comp | $4M | $4M | $6M | $7M | $10M | $10M | $424.0K | $3M | $3M | $3M | $2M | $459.0K | |
| Deferred Tax | $-11M | $-20M | $-14M | $-9M | $-5M | $-9M | · | · | · | · | · | · | |
| Restructuring | · | · | · | · | · | · | $3M | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | $1M | $2M | $-7M | |
| Operating Cash Flow | $-56M | $-36M | $-38M | $-26M | $-35M | $-23M | $-5M | $-23M | $-22M | $-24M | $-18M | $-10M | |
| CapEx | $94.0K | $63.0K | $45.0K | $120.0K | $596.0K | $884.0K | $475.0K | $119.0K | $35.0K | $271.0K | $198.0K | $51.0K | |
| Investing Cash Flow | $-139M | $19M | $53M | $15M | $-98M | $3M | $-475.0K | $18M | $-16M | $20M | $-11M | · | |
| Stock Issued | · | · | · | · | · | $74M | · | · | · | · | · | $62M | |
| Stock Repurchased | · | · | $91.0K | $90.0K | $228.0K | · | · | · | · | · | · | · | |
| Net Stock Activity | · | · | $-91.0K | $-90.0K | $-228.0K | $66M | · | · | · | · | · | $62M | |
| Financing Cash Flow | $83M | $140M | $-91.0K | $-90.0K | $-228.0K | $189M | $500.0K | $3M | $23M | $208.0K | $163.0K | · | |
| Net Change in Cash | · | · | · | · | · | · | $-13M | $-2M | $-15M | $-4M | $-29M | $66M | |
| Free Cash Flow | $-56M | $-36M | $-38M | $-27M | $-35M | $-24M | $-16M | · | · | $-24M | $-18M | $-10M |
盈利能力 5
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -257.1% | |
| Net Margin | · | · | · | · | · | -7291.4% | · | · | · | · | · | -113.4% | |
| EBITDA Margin | · | · | · | · | · | -7391.4% | · | · | · | · | · | -256.1% | |
| ROA | -29.4% | -34.2% | -42.0% | -46.1% | -25.1% | -33.2% | -98.3% | · | · | -51.4% | -28.1% | -7.4% | |
| ROE | -33.7% | -35.8% | -55.6% | -54.7% | -28.4% | -17.2% | -449.1% | · | · | -56.0% | -29.3% | 37.0% |
流动性与偿付能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 | 58.1 | 12.0 | · | · | 8.4 | 16.1 | 36.2 | |
| Quick Ratio | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 | 57.8 | 10.6 | · | · | 8.1 | 15.8 | 35.8 | |
| Interest Coverage | · | · | · | · | · | -1013.1 | · | · | · | · | · | -8.8 |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | · | · | · | · | · | 0.1 |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | · | · | · | · | · | · | · | · | · | · | · | $3M | |
| Net Income TTM | $-57M | $-45M | $-40M | $-66M | $-47M | $-34M | $-8M | $-21M | $-30M | $-29M | $-21M | $-3M | |
| Market Cap | $286M | $185M | $21M | $30M | $76M | $271M | $9M | · | · | $1.26B | $10.24B | $6.84B | |
| P/E | -4.0 | -2.4 | -0.5 | -0.5 | -1.6 | · | · | · | · | · | · | · | |
| P/S | · | · | · | · | · | · | · | · | · | · | · | 2321.1 | |
| P/B | 1.5 | 1.1 | 0.3 | 0.3 | 0.5 | 1.4 | 1.4 | · | · | 32.8 | 161.5 | 83.0 | |
| P / Tangible Book | 1.5 | 1.1 | 0.3 | 0.3 | 0.6 | 1.6 | · | · | · | · | · | · | |
| P / Cash Flow | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.6 | -0.6 | · | · | -53.3 | -582.8 | -684.9 | |
| P / FCF | -5.1 | -5.2 | -0.6 | -1.1 | -2.2 | -11.2 | -0.6 | · | · | -52.7 | -576.3 | -681.5 | |
| Earnings Yield | -25.1% | -41.1% | -190.4% | -218.7% | -62.4% | · | · | · | · | · | · | · |
损益表 12
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $17M | $14M | $13M | $10M | $11M | $9M | $9M | $8M | $6M | $8M | $6M | $6M | $7M | $5M | $5M | $3M | |
| SG&A Expense | $6M | $6M | $6M | $5M | $6M | $5M | $5M | $4M | $4M | $4M | $5M | $4M | $5M | $5M | $5M | $5M | |
| Operating Expenses | $23M | $20M | $19M | $15M | $17M | $14M | $14M | $12M | $11M | $12M | $11M | $11M | $12M | $10M | $40M | $8M | |
| Operating Income | $-23M | $-20M | $-19M | $-15M | $-17M | $-14M | $-14M | $-12M | $-11M | $-12M | $-11M | $-11M | $-12M | $-10M | $-40M | $-8M | |
| Interest Income | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Other Non-op | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $1M | $756.0K | $820.0K | $840.0K | $846.0K | $687.0K | $542.0K | $283.0K | |
| Net Income | $-22M | $-18M | $-17M | $-13M | $-15M | $-12M | $-13M | $-11M | $-10M | $-11M | $-10M | $-10M | $-11M | $-9M | $-39M | $-8M | |
| EPS (Basic) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| EPS (Diluted) | $-0.36 | $-0.31 | $-0.39 | $-0.31 | $-0.35 | $-0.29 | $-0.25 | $-0.50 | $-0.45 | $-0.97 | $-0.90 | $-0.87 | $-1.00 | $-0.80 | $-3.46 | $-0.68 | |
| Shares (Basic) | 61,006,766 | 57,538,833 | -82,414,767 | 42,272,104 | 42,270,855 | 40,707,937 | -34,391,036 | 22,329,772 | 21,233,163 | 11,420,948 | -22,628,260 | 11,347,887 | 11,307,842 | 11,303,869 | -22,511,202 | 11,265,475 | |
| Shares (Diluted) | 61,006,766 | 57,538,833 | -82,414,767 | 42,272,104 | 42,270,855 | 40,707,937 | -34,391,036 | 22,329,772 | 21,233,163 | 11,420,948 | -22,628,260 | 11,347,887 | 11,307,842 | 11,303,869 | -22,511,202 | 11,265,475 | |
| EBITDA | $-23M | $-20M | · | $-15M | $-17M | $-14M | · | $-12M | $-11M | $-12M | · | $-11M | $-12M | $-10M | · | $-8M |
资产负债表 23
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $17M | $15M | $50M | $13M | $31M | $91M | $163M | $52M | $90M | $52M | $40M | $34M | $34M | $21M | $24M | $47M | |
| Short-term Investments | $125M | $121M | $106M | $120M | $91M | $33M | $7M | $30M | · | $3M | $26M | $40M | $46M | $66M | $60M | $49M | |
| Prepaid Expense | $4M | $4M | $4M | $3M | $3M | $2M | $2M | $4M | $3M | $3M | $3M | $4M | $4M | $8M | $2M | $2M | |
| Other Current Assets | $230.0K | $17.0K | $65.0K | $218.0K | $78.0K | $16.0K | $2.0K | $3.0K | $4.0K | $3.0K | $37.0K | $2.0K | $1.0K | $127.0K | $127.0K | · | |
| Current Assets | $146M | $140M | $160M | $136M | $125M | $127M | $172M | $85M | $92M | $58M | $69M | $78M | $84M | $95M | $86M | $99M | |
| PP&E (Net) | $1M | $669.0K | $759.0K | $828.0K | $912.0K | $988.0K | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $2M | |
| PP&E (Gross) | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | · | · | $2M | · | |
| Accum. Depreciation | · | · | $1M | · | · | · | $1M | · | · | · | $824.0K | · | · | · | $483.0K | · | |
| Goodwill | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Assets | $74.0K | $76.0K | $20.0K | $21.0K | $29.0K | $35.0K | $27.0K | $33.0K | $19.0K | $31.0K | $11.0K | $3M | $3M | $586.0K | $16.0K | $734.0K | |
| Total Assets | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Accounts Payable | $5M | $4M | $3M | $5M | $5M | $2M | $4M | $2M | $1M | $972.0K | $2M | $3M | $2M | $4M | $2M | $456.0K | |
| Accrued Liabilities | $7M | $4M | $6M | $4M | $3M | $4M | $5M | $5M | $3M | $4M | $3M | $3M | $2M | $1M | $3M | $2M | |
| Current Liabilities | $13M | $9M | $11M | $10M | $10M | $7M | $11M | $9M | $6M | $6M | $6M | $7M | $5M | $6M | $6M | $4M | |
| Capital Leases | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $4M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $6M | |
| Total Liabilities | $15M | $11M | $13M | $12M | $13M | $10M | $14M | $12M | $10M | $10M | $11M | $12M | $10M | $12M | $11M | $9M | |
| Common Stock | $59.0K | $55.0K | $54.0K | $39.0K | $39.0K | $39.0K | $35.0K | $21.0K | $21.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | $11.0K | |
| Paid-in Capital | $503M | $502M | $499M | $417M | $416M | $415M | $412M | $314M | $313M | $270M | $269M | $267M | $266M | $264M | $263M | $261M | |
| Retained Earnings | $-342M | $-320M | $-302M | $-285M | $-272M | $-257M | $-245M | $-232M | $-221M | $-211M | $-200M | $-190M | $-180M | $-169M | $-160M | $-121M | |
| AOCI | $-363.0K | $-364.0K | $90.0K | $143.0K | $77.0K | $89.0K | $2.0K | $29.0K | · | $-1.0K | $-31.0K | $-165.0K | $-336.0K | $-469.0K | $-688.0K | $-1M | |
| Stockholders' Equity | $161M | $181M | $196M | $132M | $144M | $158M | $167M | $82M | $92M | $58M | $68M | $77M | $85M | $95M | $102M | $139M | |
| Liabilities + Equity | $176M | $192M | $209M | $145M | $157M | $169M | $181M | $94M | $102M | $68M | $79M | $88M | $95M | $106M | $113M | $149M | |
| Shares Outstanding | 59,083,935 | 55,055,582 | 53,587,260 | 38,587,260 | 38,581,863 | 38,577,813 | 35,044,772 | 20,629,772 | 11,364,903 | 11,433,837 | 11,364,903 | 11,364,903 | 11,307,962 | 11,306,753 | 11,267,389 | 11,267,389 |
现金流 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $1M | $1M | $1M | $1M | $903.0K | $833.0K | $904.0K | $931.0K | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $1M | |
| Operating Cash Flow | $-15M | $-21M | $-17M | $-12M | $-12M | $-15M | $-9M | $-8M | $-8M | $-10M | $-9M | $-7M | $-9M | $-13M | $-5M | $-5M | |
| CapEx | · | · | $24.0K | $4.0K | $22.0K | $44.0K | $0 | $8.0K | · | · | $0 | $37.0K | $2.0K | $6.0K | $6.0K | $83.0K | |
| Investing Cash Flow | $18M | $-15M | $-27M | $-7M | $-48M | $-58M | $22M | $-29M | $3M | $23M | $15M | $6M | $22M | $10M | $-18M | $19M | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | $76.0K | · | $27.0K | $0 | $64.0K | $0 | $18.0K | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | $-76.0K | · | · | · | $-64.0K | · | · | |
| Financing Cash Flow | $-26.0K | $1M | $81M | $13.0K | $8.0K | $2M | $98M | $0 | $42M | $-76.0K | $0 | $-27.0K | $0 | $-64.0K | $0 | $-18.0K | |
| Free Cash Flow | · | · | · | · | · | $-15M | · | · | · | · | · | · | · | $-13M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Net Margin | -1464.0% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -1575.9% | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| ROA | -13.0% | -9.9% | · | -11.1% | -11.6% | -10.1% | · | -12.3% | -9.7% | -12.7% | · | -8.3% | -9.0% | -6.8% | · | -4.7% | |
| ROE | -14.2% | -10.5% | · | -12.4% | -12.7% | -11.0% | · | -14.1% | -10.7% | -14.5% | · | -9.1% | -9.8% | -7.3% | · | -5.0% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 15.7 | · | 13.7 | 12.8 | 18.0 | · | 9.8 | 16.3 | 10.5 | · | 11.5 | 17.1 | 14.8 | · | 26.6 | |
| Quick Ratio | 10.7 | 15.2 | · | 13.4 | 12.5 | 17.7 | · | 9.4 | 15.9 | 10.0 | · | 10.9 | 16.3 | 13.5 | · | 26.0 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-68M | $-58M | · | $-51M | $-48M | $-44M | · | $-42M | $-42M | $-41M | · | $-38M | $-37M | $-36M | · | $-38M | |
| Market Cap | $226M | $287M | · | $168M | $117M | $164M | · | $38M | $24M | $46M | · | $19M | $27M | $35M | · | $33M | |
| P/E | -2.9 | -4.1 | · | -3.0 | -1.9 | -1.9 | · | -0.7 | -0.6 | -1.1 | · | -0.5 | -0.7 | -1.0 | · | -0.9 | |
| P/B | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.2 | |
| P / Tangible Book | 1.4 | 1.6 | · | 1.3 | 0.8 | 1.0 | · | 0.5 | 0.3 | 0.8 | · | 0.2 | 0.3 | 0.4 | · | 0.3 | |
| P / Cash Flow | · | -13.4 | · | · | · | -11.2 | · | · | · | -4.4 | · | · | · | -2.7 | · | · | |
| P / FCF | · | · | · | · | · | -11.1 | · | · | · | · | · | · | · | -2.7 | · | · | |
| Earnings Yield | -34.8% | -24.2% | · | -33.3% | -52.5% | -51.9% | · | -152.5% | -158.2% | -90.8% | · | -200.6% | -135.6% | -102.2% | · | -113.5% |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 净收入 | $-57M | $-45M | $-40M | $-66M | $-47M |
| 稀释后每股收益 (EPS) | $-1.34 | $-2.17 | $-3.57 | $-5.86 | $-4.21 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 14.6 | 15.7 | 11.2 | 15.0 | 21.7 |
| 速动比率 | 14.2 | 15.5 | 10.7 | 14.7 | 21.2 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-56M | $-36M | $-38M | $-27M | $-35M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 127 家申报者 · $162.3M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 31 (+4 与上一季度对比) | 16 (-5 与上一季度对比) | 39 (-8 与上一季度对比) | 33 (+10 与上一季度对比) | +760K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
公司内部人士 40 位内幕人士 · 16 位高管 · 20 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Jesse Shefferman | CEO and President | 2026年6月29日 M | 691832 | 0 | 1 | $-882160 |
| Timothy P Noyes | President and CEO | 2019年1月31日 A | 0 | 0 | 0 | $0 |
| Patrick Fabbio | Chief Financial Officer | 2026年1月26日 F | 64115 | 0 | 0 | $0 |
| Blaine Davis | Chief Financial Officer | 2022年7月15日 F | 20662 | 0 | 0 | $0 |
| George Arthur Eldridge, | Sr VP, CFO, Treasr, Asst Secy | 2019年1月18日 A | 29132 | 0 | 0 | $0 |
| William Conkling | Chief Commercial Officer | 2026年6月2日 F | 69992 | 0 | 0 | $0 |
| Jacqueline Zummo | Chief R&D Officer | 2026年4月8日 S | 94827 | 0 | 2 | $-124989 |
| Hannah Fry | VP, Controller | 2026年1月26日 F | 42723 | 0 | 0 | $0 |
| Leonardo Viana Nicacio | Chief Medical Officer | 2026年1月16日 A | 78181 | 0 | 0 | $0 |
| Jathin Bandari | Chief Medical Officer | 2024年1月19日 A | 56704 | 0 | 0 | $0 |
| Julio Casoy | Chief Medical Officer | 2020年1月9日 A | 45500 | 0 | 0 | $0 |
| Steven Keith Burke | SVP and Chief Medical Officer | 2019年3月15日 G | 26332 | 0 | 0 | $0 |
| Bradley J Hartman | VP, People | 2019年1月18日 A | — | 0 | 0 | $0 |
| Matthew Paul Kowalsky | VP, Legal and Secretary | 2019年1月18日 A | 29479 | 0 | 0 | $0 |
| Scott E. Toner | Senior VP of Commercial | 2019年1月18日 A | 23357 | 0 | 0 | $0 |
| Gottlieb Daniel Philip | VP Corporate Development | 2019年1月18日 A | 244 | 0 | 0 | $0 |
| Michael Edward Solomon | 董事 | 2026年6月15日 A | 26500 | 0 | 0 | $0 |
| Jane Huang | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Barry P Flannelly | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Cynthia Smith | 董事 | 2026年6月15日 A | — | 0 | 0 | $0 |
| Richard S Levy | 董事 | 2026年6月15日 A | 51000 | 0 | 0 | $0 |
| Roger Garceau | 董事 | 2026年6月15日 A | 33000 | 0 | 0 | $0 |
| Gregory Sargen | 董事 | 2026年6月15日 A | 31000 | 0 | 0 | $0 |
| Luke M Beshar | 董事 | 2026年6月15日 A | 198000 | 0 | 0 | $0 |
| Scott Braunstein | 董事 | 2020年6月9日 A | 26500 | 0 | 0 | $0 |
| John Gordon Freund | 董事 | 2019年11月8日 C | 2175882 | 0 | 0 | $0 |
| Hubert Birner | 董事 | 2018年6月8日 A | 1943059 | 0 | 0 | $0 |
| Paul J Hastings | 董事 | 2018年6月8日 A | — | 0 | 0 | $0 |
| Scott A Canute | 董事 | 2018年6月8日 A | — | 0 | 0 | $0 |
| Garen G Bohlin | 董事 | 2018年6月8日 A | 53312 | 0 | 0 | $0 |
| Jonathan S Leff | 董事 | 2018年6月8日 A | — | 0 | 0 | $0 |
| Brendan O'Leary | 董事 | 2016年6月9日 A | 1387198 | 0 | 0 | $0 |
| Dmitry Kobyzev | 董事 | 2015年6月2日 A | 1165344 | 0 | 0 | $0 |
| Gregory D Phelps | 董事 | 2015年6月2日 A | — | 0 | 0 | $0 |
| Opaleye, L.P. | 10% 所有者 | 2020年1月9日 A | 2208472 | 0 | 0 | $0 |
| Martin Sebastian Olivo | — | 2021年6月10日 P | 14344 | 0 | 0 | $0 |
| Randall Marshall | — | 2020年9月14日 S | 585600 | 0 | 0 | $0 |
| Timothy Haines | — | 2019年11月12日 C | 2144517 | 0 | 0 | $0 |
| Abingworth LLP | — | 2019年11月12日 C | 2144517 | 0 | 0 | $0 |
| Stuart A Kingsley | — | 2018年6月8日 A | — | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 8 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn | 2021年1月8日 | — | 初始申报 | — | SEC |
| Opaleye Management Inc., Opaleye, L.P., James Silverman ×3 申报 | 2020年9月25日 | — | 初始申报 | — | SEC |
| Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., James E. Flynn ×6 申报 | 2020年1月17日 | — | 初始申报 | — | SEC |
| Abingworth LLP, Abingworth Bioventures VI, LP | 2020年1月17日 | — | 初始申报 | 并购/出售 | SEC |
| Abingworth LLP 98-051-8585, Abingworth Bioventures VI, LP 98-040-3543 ×3 申报 | 2019年11月14日 | — | 初始申报 | 董事会活动 | SEC |
| TVM Life Science Ventures VI L.P., TVM Life Science Ventures VI GmbH & Co. KG, TVM Life Science Ventures Management VI L.P., Hubert Birner, Stefan Fischer, Helmut Schuehsler ×2 申报 | 2017年8月2日 | — | 初始申报 | 被动投资 | SEC |
| Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Mgmt III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., James E. Flynn | 2017年6月29日 | — | 初始申报 | 被动投资 | SEC |
| Skyline Venture Partners Qualified Purchaser Fund IV, L.P., Skyline Venture Management IV, LLC, John G. Freund, Yasunori Kaneko | 2014年11月3日 | — | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 22 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 0.16% | 55748 NS | 2026年5月31日 | N-PORT |
| IWC · iShares Trust | 0.05% | 175831 SH | 2026年8月8日 | 每日 |
| VFMO · VANGUARD WELLINGTON FUND | 0.03% | 141979 SH | 2026年8月8日 | 每日 |
| AVSC · AMERICAN CENTURY ETF TRUST | 0.02% | 91844 NS | 2026年5月31日 | N-PORT |
| IWN · iShares Trust | 0.01% | 470658 SH | 2026年8月8日 | 每日 |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 300912 SH | 2026年8月8日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.01% | 45581 SH | 2026年8月8日 | 每日 |
| RSSL · Global X Funds | 0.01% | 22265 NS | 2026年4月30日 | N-PORT |
| IWM · iShares Trust | 0.01% | 1336607 SH | 2026年8月8日 | 每日 |
| DFAS · Dimensional ETF Trust | 0.01% | 179929 NS | 2026年4月30日 | N-PORT |
| ITWO · ProShares Trust | 0.01% | 2419 NS | 2026年5月31日 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.01% | 3715 NS | 2026年4月30日 | N-PORT |
| UWM · ProShares Trust | 0.00% | 1891 NS | 2026年5月31日 | N-PORT |
| URTY · ProShares Trust | 0.00% | 1912 NS | 2026年5月31日 | N-PORT |
| HDG · ProShares Trust | 0.00% | 48 NS | 2026年5月31日 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 5791 NS | 2026年4月30日 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.00% | 18477 NS | 2026年4月30日 | N-PORT |
| DFUS · Dimensional ETF Trust | 0.00% | 7914 NS | 2026年4月30日 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 20174 NS | 2026年4月30日 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 586965 SH | 2026年8月8日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 1657879 SH | 2026年8月8日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 3185 SH | 2026年8月8日 | 每日 |